# MerLion Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/merlion-pharma

- Industry: Pharmaceuticals
- Headquarters: Singapore, Singapore
- Website: www.merlionpharma.com
- Total disclosed funding: $26M
- Latest round: Series C (Oct 11, 2010)
- Investors on record: 10

## About

MerLion Pharma is a pharmaceutical company focused on developing innovative antibiotics to combat bacterial infections, particularly targeting antibiotic-resistant pathogens.Founded in 2002 and headquartered in Singapore, MerLion Pharma specializes in antibiotic development. The company has raised USD 2.73 mn in its recent GROWTH funding round in November 2016, bringing the total amount raised to USD 2.73 mn and valuing the company at USD 45.05 mn. Founded by a team with a strong background in pharmaceuticals, MerLion has successfully completed five deals to date. With no pivots or subsidiary relationships mentioned, the company maintains a clear focus on its antibiotic innovations.MerLion Pharmaceuticals specializes in the development of innovative antibiotics, with a primary focus on its core product, Finafloxacin, a next-generation fluoroquinolone antibiotic. Finafloxacin has unique properties that make it one of the safest and fastest-acting antibiotics in its class. This drug has received regulatory approval from the US FDA and Health Canada for the treatment of acute otitis externa (ear infections), marketed under the brand name Xtoro™. In addition to ear infections, MerLion is advancing Finafloxacin for the treatment of complicated urinary tract infections (cUTIs), demonstrating efficacy through successful phase II clinical trials. The company's products are aimed at healthcare providers and institutions in North America and select international markets, addressing critical healthcare needs by providing effective solutions against bacterial infections, including those caused by antibiotic-resistant pathogens.In the most recent year, MerLion Pharmaceuticals reported revenues of USD 222,938.70 from direct sales of its products, particularly Xtoro™, to hospitals and clinics. The company also engages in collaborations with defense agencies for further applications of Finafloxacin, contributing to its revenue through bulk purchase agreements with healthcare facilities and distributors. The EBITDA for the same year was USD 2,446,772.40, reflecting the company's structured revenue model through partnerships and direct sales.MerLion Pharma plans to utilize the recent GROWTH financing of USD 2.73 mn to expand its product line and enhance market penetration. The funds will support the launch of new applications for Finafloxacin beyond its current indications. Additionally, the company intends to target new markets in Europe and Asia by 2020, capitalizing on the increasing demand for effective antibiotic solutions. The strategic focus will also include bolstering collaborations with healthcare institutions to ensure wider accessibility to its antibiotic products, aligning with its commitment to address urgent healthcare challenges.

## Funding rounds

- Series C, Oct 11, 2010, $7M — Aravis, Aurelia Private Equity, SG Growth Capital
- Series B, Nov 1, 2006, $5M — Zürcher Kantonalbank, Commerce Ventures
- Series A, Oct 30, 2002, $14M — Temasek Holdings, Aravis, BioVeda Capital, Novartis Venture Fund, Biomedical Sciences Investment Fund, JIF Capital

## Investors

- Temasek Holdings — Series A
- Aravis (https://capitalatlas.ai/funds/aravis) — Series A, Series C
- BioVeda Capital (https://capitalatlas.ai/funds/bioveda-capital) — Series A
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A
- Biomedical Sciences Investment Fund — Series A
- JIF Capital (https://capitalatlas.ai/funds/jif-capital) — Series A
- Zürcher Kantonalbank — Series B
- Commerce Ventures (https://capitalatlas.ai/funds/commerce-ventures) — Series B
- Aurelia Private Equity (https://capitalatlas.ai/funds/aurelia-private-equity) — Series C
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series C